Genmab stock trades in the mid-$30s on Nasdaq as updated 2026 revenue guidance leans more heavily on

Biotech firms ProfoundBio and Genmab urged a Seattle federal judge Thursday to throw out rival AbbVie's lawsuit accusing two of its former employees of taking trade secrets on cancer therapies to ProfoundBio, arguing AbbVie's claims are time-barred, and the information wasn't a protectable trade secret.

Genmab A/S (NASDAQ:GMAB) boosted its full-year 2026 revenue guidance to a range of $4.325 billion to $4.525 billion, up from its previous outlook of $4.065 billion to $4.395 billion. The upward revision underscores the strong commercial momentum across the company’s royalty streams and proprietary portfolio. For the first half of 2026, GMAB reported total revenue […]

Genmab stock is trading steadily after the company highlighted its June 30, 2026 interim results and

Genmab stock edges lower as executives prepare for a trio of September 2026 investor conference fire

Media ReleaseCOPENHAGEN, Denmark; August 25, 2026Genmab A/S (Nasdaq: GMAB) announced today that members of its Executive Committee will participate in fireside chats at the following investor conferences in September 2026: Wells Fargo 21st Annual Healthcare Conference in Boston on September 9, 2026, 3:00 PM EDT24th Annual Morgan Stanley Global Healthcare Conference in New York City on September 15, 2026, 8:30 AM EDTBank of America Global Healthcare Conference in London on September 22, 2026, 10: